Zevra Therapeutics, Inc. is rated a Buy, delivered robust FY25 results, with 350% revenue growth to $106.5M. Learn more about ZVRA stock here.
Find the best actuarial exam prep courses. Expert reviews of top platforms, including lifetime access, adaptive learning, and free options.
Good morning, and welcome to OppFi's Fourth Quarter 2025 Earnings Call. Today, our Executive Chairman and CEO, Todd Schwartz. and CFO Pam Joh ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.
Engineers leverage both device-specific and tool-level data to identify a process “sweet spot.” Tight, frequent tool-to-tool matching enables greater yield and fab flexibility. Machine learning helps ...
Apple’s new lower-price Mac is the best choice for most people ...
Live Science spoke with the scientists behind an upcoming clinical trial testing an immune therapy for depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results